Palvella director granted 3,000 stock options

Palvella Therapeutics director Tadd S. Wessel received a grant of stock options covering 3,000 shares of common stock.

Rhea-AI Filing Summary

Palvella Therapeutics director Tadd S. Wessel received a grant of stock options covering 3,000 shares of common stock. The options have an exercise price of $102.19 per share and expire on June 10, 2036. All 3,000 options are held directly after this transaction. The options vest on the earlier of the first anniversary of the June 10, 2026 grant date or the date of Palvella’s next annual meeting of stockholders, in each case requiring his continued service through the vesting date. This is a compensation-related grant, not an open-market share purchase or sale.

Insider Trade Summary

Grant/Award: 3,000 shares

Grant/Award 1 txn

Insider Wessel Tadd S.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	3,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 3,000 contracts (Direct)

Footnotes (1)

1. F1. The shares subject to this option shall vest upon the earlier of (i) the first anniversary of the grant date or (ii) the date of the Issuer's next annual meeting of stockholders following the grant date, subject in each case to the Reporting Person's continued service through the applicable vesting date.

Key Figures

Options granted: 3,000 options Exercise price: $102.19 per share Underlying shares: 3,000 shares +2 more

5 metrics

Options granted 3,000 options Stock Option (Right to Buy) grant on June 10, 2026

Exercise price $102.19 per share Conversion or exercise price of granted options

Underlying shares 3,000 shares Common stock covered by the option grant

Expiration date June 10, 2036 Option grant expiration

Post-transaction options 3,000 options Total derivative holdings after this transaction

Key Terms

Stock Option (Right to Buy), grant/award acquisition, annual meeting of stockholders, vesting date

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

grant/award acquisition financial

"transaction_action: grant/award acquisition"

annual meeting of stockholders financial

"the Issuer's next annual meeting of stockholders following the grant date"

vesting date financial

"continued service through the applicable vesting date"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Palvella Therapeutics (PVLA) report for Tadd S. Wessel?

Palvella Therapeutics reported that director Tadd S. Wessel received a grant of stock options for 3,000 shares of common stock. The options were awarded as compensation, not bought on the market, and give him the right to purchase shares at a fixed exercise price.

How many Palvella Therapeutics (PVLA) options were granted and at what price?

Tadd S. Wessel was granted stock options on 3,000 shares of Palvella Therapeutics common stock. The options carry an exercise price of $102.19 per share, meaning he can buy shares at that price once the options vest and are exercisable.

When do Tadd S. Wessel’s Palvella Therapeutics (PVLA) options vest?

The 3,000 stock options granted to Tadd S. Wessel vest on the earlier of the first anniversary of the June 10, 2026 grant date or Palvella’s next annual meeting of stockholders. Vesting is conditioned on his continued service through the applicable vesting date.

When do the newly granted Palvella Therapeutics (PVLA) options expire?

The granted stock options expire on June 10, 2036. After that expiration date, any unexercised options will lapse and no longer allow purchase of Palvella Therapeutics common stock at the fixed $102.19 per share exercise price specified in the award.

Is Tadd S. Wessel buying or selling Palvella Therapeutics (PVLA) shares in this Form 4?

This Form 4 reports an acquisition of derivative securities through a grant, not a market trade. Tadd S. Wessel received 3,000 stock options as compensation, with no open-market buying or selling of Palvella Therapeutics common stock disclosed in this transaction.

How many Palvella Therapeutics (PVLA) options does Tadd S. Wessel hold after this grant?

Following this reported transaction, Tadd S. Wessel holds 3,000 stock options directly. These options relate to 3,000 underlying shares of Palvella Therapeutics common stock and reflect his position from this specific award as reported in the filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/12/2026 - 04:05 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wessel Tadd S.

(Last) (First) (Middle)

C/O PALVELLA THERAPEUTICS, INC.

353 W. LANCASTER AVENUE, SUITE 200

(Street)

WAYNE PENNSYLVANIA 19087

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PALVELLA THERAPEUTICS, INC. [ PVLA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$102.19	06/10/2026		A		3,000		(1)	06/10/2036	Common Stock	3,000	$0	3,000	D

Explanation of Responses:

1. The shares subject to this option shall vest upon the earlier of (i) the first anniversary of the grant date or (ii) the date of the Issuer's next annual meeting of stockholders following the grant date, subject in each case to the Reporting Person's continued service through the applicable vesting date.

	/s/ Kathleen A. McGowan, Attorney-in-Fact	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)